Restraining CDK1–cyclin B activation: PP2A on the cUSP(7)

Marilynn Chow-Castro, Shandee D. Dixon, Joshua C. Saldivar

Research output: Contribution to journalComment/debatepeer-review

Abstract

USP7 inhibitors are gaining momentum as a therapeutic strategy to stabilize p53 through their ability to induce MDM2 degradation. However, these inhibitors come with an unexpected p53-independent toxicity, via an unknown mechanism. In this issue of The EMBO Journal, Galarreta et al report how inhibition of USP7 leads to re-distribution of PP2A from cytoplasm to nucleus and an increase of deleterious CDK1-dependent phosphorylation throughout the cell cycle, revealing a new regulatory mechanism for the progression of S-phase cells toward mitosis to maintain genomic integrity.

Original languageEnglish (US)
Article numbere108486
JournalEMBO Journal
Volume40
Issue number11
DOIs
StatePublished - Jun 1 2021

ASJC Scopus subject areas

  • Neuroscience(all)
  • Molecular Biology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Fingerprint

Dive into the research topics of 'Restraining CDK1–cyclin B activation: PP2A on the cUSP(7)'. Together they form a unique fingerprint.

Cite this